Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

Alexandros Papachristofilou; Madeleine M. Hipp; Ute Klinkhardt; Martin Früh; Martin Sebastian; Christian Weiss; Miklos Pless; Richard Cathomas; Wolfgang Hilbe; Georg Pall; Thomas Wehler; Jürgen Alt; Helge Bischoff; Michael Geißler; Frank Griesinger; Karl-Josef Kallen; Mariola Fotin-Mleczek; Andreas Schröder; Birgit Scheel; Anke Muth; Tobias Seibel; Claudia Stosnach; Fatma Doener; Henoch S. Hong; Sven D. Koch; Ulrike Gnad-Vogt; Alfred Zippelius

doi:10.1186/s40425-019-0520-5

Citation Tools

XML

Research Article

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Papachristofilou A, Hipp MM, Klinkhardt U, et al

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

Journal for ImmunoTherapy of Cancer 2019;7:38. doi: 10.1186/s40425-019-0520-5

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password